NRAS-MUTANT ADVANCED MELANOMA
Clinical trials for NRAS-MUTANT ADVANCED MELANOMA explained in plain language.
Never miss a new study
Get alerted when new NRAS-MUTANT ADVANCED MELANOMA trials appear
Sign up with your email to follow new studies for NRAS-MUTANT ADVANCED MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug hopes to shrink NRAS-Driven cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…
Matched conditions: NRAS-MUTANT ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for advanced melanoma: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called tunlametinib in people with advanced melanoma that has a specific NRAS gene change and has not responded to prior immunotherapy. About 110 adults will take the drug by mouth to see if it can shrink tumors and how safe it is. The goal is to control t…
Matched conditions: NRAS-MUTANT ADVANCED MELANOMA
Phase: PHASE4 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC